{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:58:32Z","timestamp":1791215912117,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tcmonline.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.tcm.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T17:25:18Z","timestamp":1434389118000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Angiotensin receptor blockers: Focus on cardiac and renal injury"],"prefix":"10.1016","volume":"26","author":[{"given":"Somasundaram","family":"Arumugam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya","family":"Sreedhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarajan A.","family":"Thandavarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vengadeshprabhu","family":"Karuppagounder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2015.06.004_bib1","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.bbamem.2011.08.001","article-title":"Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers","volume":"1808","author":"Ntountaniotis","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tcm.2015.06.004_bib2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.molimm.2011.05.008","article-title":"AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes","volume":"48","author":"Silva-Filho","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.tcm.2015.06.004_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tox.2011.11.008","article-title":"Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis","volume":"291","author":"Arumugam","year":"2012","journal-title":"Toxicology"},{"key":"10.1016\/j.tcm.2015.06.004_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.mce.2011.12.010","article-title":"Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor","volume":"351","author":"Sukumaran","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.tcm.2015.06.004_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/ecp.10.141","article-title":"Telmisartan for the reduction of cardiovascular morbidity and mortality","volume":"4","author":"Verdecchia","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.tcm.2015.06.004_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1291\/hypres.30.1205","article-title":"Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients","volume":"30","author":"Chujo","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1016\/j.tcm.2015.06.004_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijcard.2012.09.044","article-title":"Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials","volume":"165","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cca.2011.09.024","article-title":"Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients","volume":"413","author":"Utsumi","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.tcm.2015.06.004_bib9","first-page":"678","article-title":"Olmesartan for the prevention or delay of diabetic nephropathy: some considerations","volume":"65","author":"Catala-Lopez","year":"2012","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.tcm.2015.06.004_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2011.10.013","article-title":"Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial","volume":"220","author":"Hirohata","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2015.06.004_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijcard.2014.06.013","article-title":"Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis","volume":"175","author":"Bang","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2011.08.056","article-title":"Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement","volume":"165","author":"Dahl","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.metabol.2010.11.004","article-title":"Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells","volume":"60","author":"Wang","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.tcm.2015.06.004_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.phrs.2010.11.001","article-title":"The effect of losartan treatment on the response of diabetic cardiomyocytes to ATP depletion","volume":"63","author":"Alfarano","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.tcm.2015.06.004_bib15","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1161\/CIRCULATIONAHA.110.012187","article-title":"Pravastatin reduces Marfan aortic dilation","volume":"124","author":"McLoughlin","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2015.06.004_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.archger.2010.04.022","article-title":"Losartan vs. amlodipine treatment in elderly oncologic hypertensive patients: a randomized clinical trial","volume":"53","author":"Motta","year":"2011","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.tcm.2015.06.004_bib17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.mehy.2012.05.011","article-title":"The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients","volume":"79","author":"Parlak","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.tcm.2015.06.004_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.acvd.2010.12.005","article-title":"Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study","volume":"104","author":"Lins","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.tcm.2015.06.004_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diabres.2012.01.037","article-title":"Valsartan inhibited HIF-1alpha pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats","volume":"97","author":"Tang","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.tcm.2015.06.004_bib20","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.ijcard.2012.06.128","article-title":"Valsartan impairs angiogenesis of mesenchymal stem cells through Akt pathway","volume":"167","author":"Cheng","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2011.07.051","article-title":"Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study","volume":"161","author":"Doehner","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mvr.2011.01.001","article-title":"Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells","volume":"81","author":"Matsui","year":"2011","journal-title":"Microvasc Res"},{"key":"10.1016\/j.tcm.2015.06.004_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.tcm.2015.06.004_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF03261917","article-title":"Azilsartan medoxomil: a review of its use in hypertension","volume":"32","author":"Perry","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.tcm.2015.06.004_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FJC.0b013e318297458b","article-title":"Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial","volume":"62","author":"Lee","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.tcm.2015.06.004_bib26","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.ijcard.2013.03.151","article-title":"Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia\/reperfusion injury","volume":"168","author":"Han","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2015.06.004_bib27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.clinthera.2011.07.002","article-title":"Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension","volume":"33","author":"Lee","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.tcm.2015.06.004_bib28","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.clinthera.2012.06.004","article-title":"The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial","volume":"34","author":"Gu","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.tcm.2015.06.004_bib29","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2165\/00003495-200565160-00012","article-title":"Eprosartan: a review of its use in the management of hypertension","volume":"65","author":"Robins","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.tcm.2015.06.004_bib30","first-page":"77","article-title":"Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia","volume":"85","author":"Kaliuzhin","year":"2013","journal-title":"Ter Arkh"},{"key":"10.1016\/j.tcm.2015.06.004_bib31","doi-asserted-by":"crossref","unstructured":"Hanon O, Lee YS, Pathak A, on behalf of the OPG. Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study. J Renin Angiotensin Aldosterone Syst 2013. 10.1177\/1470320313491795.","DOI":"10.1177\/1470320313491795"},{"key":"10.1016\/j.tcm.2015.06.004_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000139534","article-title":"Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade","volume":"55","author":"Ohlstein","year":"1997","journal-title":"Pharmacology"},{"key":"10.1016\/j.tcm.2015.06.004_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00019053-200321010-00005","article-title":"Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan","volume":"21","author":"Simons","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.tcm.2015.06.004_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2011.07.014","article-title":"Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models","volume":"669","author":"Kusumoto","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.tcm.2015.06.004_bib35","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/HJH.0b013e32834c46fd","article-title":"Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker","volume":"29","author":"Kajiya","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.tcm.2015.06.004_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/14779072.2014.924853","article-title":"Efficacy of azilsartan medoxomil with chlorthalidone in hypertension","volume":"12","author":"Baker","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.tcm.2015.06.004_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1753944713498638","article-title":"Management of hypertension with fixed-dose triple-combination treatments","volume":"7","author":"Epstein","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.tcm.2015.06.004_bib38","doi-asserted-by":"crossref","first-page":"15361","DOI":"10.3390\/ijms140815361","article-title":"Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease","volume":"14","author":"Ohsawa","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2015.06.004_bib39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol Rev"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017381500170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017381500170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T19:54:37Z","timestamp":1537559677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105017381500170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S105017381500170X"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2015.06.004","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin receptor blockers: Focus on cardiac and renal injury","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}